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Abstract Purpose: The study
aimed to develop a gastrointestinal
(GI) dysfunction score predicting
28-day mortality for adult patients
needing mechanical ventilation
(MV). Methods: 377 adult patients
from 40 ICUs with expected duration
of MV for at least 6 h were prospec-
tively studied. Predefined GI
symptoms, intra-abdominal pressures
(IAP), feeding details, organ dys-
function and treatment were
documented on days 1, 2, 4 and 7.
Results: The number of simulta-
neous GI symptoms was higher in
nonsurvivors on each day. Absent
bowel sounds and GI bleeding were
the symptoms most significantly
associated with mortality. None of the
GI symptoms alone was an indepen-
dent predictor of mortality, but
gastrointestinal failure (GIF)—
defined as three or more GI
symptoms—on day 1 in ICU was
independently associated with a
threefold increased risk of mortality.
During the first week in ICU, GIF
occurred in 24 patients (6.4 %) and
was associated with higher 28-day
mortality (62.5 vs. 28.9 %,
P = 0.001). Adding the created sub-
score for GI dysfunction (based on
the number of GI symptoms) to
SOFA score did not improve mortal-
ity prediction (day 1 AUROC 0.706
[95 % CI 0.647–0.766] versus 0.703
[95 % CI 0.643–0.762] in SOFA
score alone). Conclusions: An
increasing number of GI symptoms
independently predicts 28 day mor-
tality with moderate accuracy.
However, it was not possible to
develop a GI dysfunction score,
improving the performance of the
SOFA score either due to data set
limitations, definition problems, or
possibly indicating that GI dysfunc-
tion is often secondary and not the
primary cause of other organ failure.
Keywords Gastrointestinal
symptoms  Gastrointestinal
dysfunction  Intensive care 
Outcome
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Introduction
Gastrointestinal (GI) problems in critically ill patients are
common and associated with impaired outcome [1–4].
The hypothesis of the gut as a motor of multiple organ
failure (MOF) has repeatedly been proposed in the past
[5, 6]. Despite this, the pathophysiological role of GI
dysfunction in the clinical course of MOF has not been
sufficiently investigated. In a recent consensus statement,
the working group on abdominal problems (WGAP) of
the European Society of Intensive Care Medicine pro-
posed a terminology aiming to provide clinical
definitions, although evidence-based criteria for these
definitions were limited [7].
The sequential organ failure assessment (SOFA) score,
widely used to assess organ dysfunction in critically ill
patients, does not take GI dysfunction into account [8]. A
previous single-centre study demonstrated that the addi-
tion of a GIF score based on the combination of feeding
intolerance (FI) and intra-abdominal hypertension (IAH)
to the original SOFA score improved the predictive power
of the latter [9].
The primary aim of this multicentre study was to
develop a GI dysfunction score predicting 28-day mor-
tality, among adult mechanically ventilated patients. A
secondary aim was to study the possible additive value of
GI dysfunction score to SOFA score on outcome predic-
tion. Thus, the hypothesis tested was that symptoms of GI
dysfunction could be used as predictors of outcome sep-
arately and/or as part of the SOFA score.
Methods
General
In this prospective, observational, multicentre study, 40
ICUs around the world participated. Study units were
asked to include consecutive adult patients (18 years and
older) with expected duration of MV of at least 6 h.
Patients who were spontaneously breathing on admission
day were not included, even if they required MV later
during their ICU stay. Patients in whom transvesical intra-
abdominal pressure (IAP) measurements were not possi-
ble for any reason, such as previous cystectomy, were
excluded. The inclusion period ranged from two to four
weeks in the different sites between October and
December 2009. Local Ethics Committees for each
country approved the study. Informed consent was
obtained from next of kin or waived (due to the obser-
vational design) according to local ethical rules. The
study protocol was endorsed by the clinical trials working
group of the World Society of Abdominal Compartment
Syndrome (WSACS trial number 013, www.wsacs.org) as
well as by the WGAP and ECCRN of the ESICM.
Power analysis based on earlier single-centre study [9]
indicated that 343 patients should be analyzed to detect a
5 % increase in the predictive capability between SOFA
and GIF score (based on the AUC of the ROC curve of the
SOFA score of 0.840 (SD 0.25)). However, as the GIF
score for current study was not predefined, but had to be
developed during the study, we aimed to enroll 500
patients.
Demographic and base-line clinical data (clinical
profile, previous surgery, presence/absence of sepsis [10],
APACHE II—acute physiology and chronic health eval-
uation II—score [11] and blood lactate concentration)
were collected on the day of ICU admission.
Predefined GI symptoms, IAP (minimum, maximum
and mean daily values), feeding details, SOFA score with
all its sub-scores, urine output, fluid balance, positive end-
expiratory pressure, as well as serum albumin and
C-reactive protein levels were documented on days 1, 2, 4
and 7 in the ICU. Caloric needs were calculated as
20 kcal/kg/day for day one and as 25 kcal/kg/day the
following study days. Survival data were collected on day
28 after ICU admission. An electronic case report file was
used for data collection.
Definitions
The following definitions were used for uniform data
collection:
Patient category: medical = no surgery within
4 weeks preceding ICU admission; elective surgical =
surgery within 4 weeks preceding admission, scheduled
[24 h in advance; emergency surgical = surgery within
4 weeks preceding admission, scheduled within 24 h of
operation.
GI symptoms were defined as follows:
High gastric residual volumes (GRV) = maximum
GRV above 500 ml at least once. Absent bowel sounds
(BS) = BS were not heard on careful auscultation.
Vomiting/regurgitation = visible vomiting or regurgita-
tion in any amount. Diarrhoea = loose or liquid stool
three or more times per day. Bowel distension = sus-
pected or radiologically confirmed bowel dilatation in any
bowel segment. GI bleeding = visible appearance of
blood in vomits, nasogastric aspirate, or stool.
Feeding intolerance (FI) was considered present when
less than 20 % of the calculated caloric needs were
administered with enteral nutrition (EN) and at the same
time GI symptom(s) were documented being a reason for
withholding or reducing the EN.
Intra-abdominal hypertension (IAH) = mean IAP of
the day C12 mmHg [12] and abdominal compartment
syndrome (ACS) = mean IAP [20 mmHg with new
organ dysfunction or failure [12], with IAP measured in
the supine position with zero-point at mid-axillary line
with a maximal instillation volume of 25 ml.
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Statistical analysis
Statistical Package for the Social Sciences (IBM SPSS
Statistics 20.0, Somers, NY, USA) software was used for
statistical analysis. Data are presented median (inter-
quartile range) if not stated otherwise. Kolmogorov–
Smirnov test with Lilliefors correction was used to test
normality of distribution. To compare groups, Student’s t-
test (normal distribution) and Mann–Whitney U test (non-
Gaussian distribution) were used for continuous variables,
and Chi-square test for categorical variables.
Univariate analyses of admission parameters were
applied to identify the risk factors for 28-day mortality.
Parameters with P \ 0.2 in univariate analysis were
entered stepwise into a multiple logistic regression model
to identify the best combination for prediction of 28-day
mortality. Single variables or subscores were preferred
against the total SOFA score. Kaplan–Meier curves and
log-rank tests were used to compare survival of patients
with and without GI symptoms.
GI symptoms were entered separately into a regression
model predicting mortality to evaluate the importance of
individual GI symptoms.
Receiver operating characteristic (ROC) curves were
used to determine the likelihood ratios of different ver-
sions of possible gastrointestinal failure (GIF) scores, the
SOFA score and the SOFA with GIF scores combined to
predict the ICU mortality. The optimal cut-off value was
calculated from the ROC curve analysis as the point with
the greatest combined sensitivity and specificity. A
P value \0.01 was considered significant, adjusting for
multiple comparisons.
Results
377 patients from 40 ICUs were included. The study flow-
chart is presented in Fig. 1. Admission and day 1 char-
acteristics with P \ 0.2 for associations with mortality in
univariate analyses are presented in Table 1.
Admission diagnosis was gastrointestinal in 27.3 %,
(including hepatopancreatic pathology in 6.6 %), pul-
monary 19.1 %, cardiac 17.2 %, neurological 15.9 % and
polytrauma in 8.7 %. Other admission diagnoses included
renal and vascular pathologies, burns and others. Most
common reasons for admission were respiratory failure
(22.5 %), shock (18.3 %), postoperative MV after major
surgery (17.8 %) and neurological deterioration (16.2 %).
Median duration of MV was 4.0 (2–13), ICU stay 7.0
(3–17) and hospital stay 19.0 (10–28) days. Mean
APACHE II score on admission was 19.0 (SD 8.0) points,
278 patients (73.7 %) were treated with vasoactive/ino-
tropic agents. The overall 28 day mortality was 31.0 %.
142/377 patients (37.7 %) had a medical profile, 78
(20.7 %) were elective and 157 (41.6 %) emergency
surgery patients; respective mortality rates were 40.8,
17.9 and 28.7 %. One-third of the elective surgery
patients underwent cardiovascular, one-third GI, and one-
third other surgical procedures.
Daily and global incidences of GI symptoms and IAH
for all patients, and for survivors and non-survivors sep-
arately are presented in Table 2. The number of
coincident GI symptoms was higher in non-survivors on
each day. None of the patients had more than four GI
symptoms simultaneously.
The incidence of absent BS was 37.7 % (mortality rate
38.0 %), of overt GI bleeding 6.4 % (mortality rate
54.2 %), of IAH 42.7 % (mortality rate 31.1 %) and of
ACS 3.6 % (mortality rate 38.5 %). FI occurred in 140
patients (37.1 %). Prepyloric route for EN was common,
postpyloric route was used in 4.3 % on day 1, increasing
to 12.9 % on day 7.
Multivariate regression analyses for 28 day mortality
including the different GI symptoms, caloric intake
\80 % and IAH are presented in Table 3. The occurrence
of absent BS on day 1, GI bleeding during the first two
days and bowel distension on day 7 were independently
associated with 28 day mortality, while vomiting, high
GRV, diarrhoea and the presence of IAH were not
predictive.
The reasons for withholding/stopping EN were not
documented in 58 % of the cases, and therefore in these
cases the presence or absence of FI could not be assessed.
EN \ 80 % of caloric needs on day 1 and 2 was associ-
ated with better survival.
Fig. 1 Enrolment flow-chart
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Based on daily comparisons of survivors and nonsur-
vivors with different number of GI symptoms (Table 2) as
well as Kaplan–Meier curves with maximum number of
GI symptoms, the cut-off point for GIF was defined as
three or more coincident GI symptoms listed above.
Gastrointestinal failure (three or more coincident GI
symptoms) occurred in 24 patients (6.4 %) and was
associated with higher 28-day mortality (62.5 vs. 28.9 %)
(Fig. 2).
Prediction of 28 day mortality in a statistical model
including demographic data and admission day variables
identified in univariate analyses, GI symptoms and SOFA
sub-scores on admission day is presented in Table 4. The
occurrence of GIF on day 1 was associated with a
threefold increased mortality, being an independent pre-
dictor of mortality together with renal and neurological
SOFA sub-score. None of the GI symptoms alone nor
IAH or caloric intake \80 % independently predicted
mortality.
Regression analyses including daily SOFA sub-scores
and the number of GI symptoms revealed increasing
number of GI symptoms as an independent predictor of
mortality on day 2 and 7 with a tendency towards sta-
tistical significance on admission and day 4 (Table 5).
Only the neurological SOFA score predicted mortality on
all study days, renal SOFA score was predictive at three
of the 4 days, haematologic SOFA on one day, while
none of the other SOFA sub-scores predicted mortality.
The best GIF score with respect to mortality prediction
included all six GI symptoms, but not IAH, FI and/or
caloric intake, giving points as follows: 0 = no GI
symptoms; 1 = 1 GI symptom; 2 = 2 GI symptoms;
3 = 3 GI symptoms and 4 C 4 GI symptoms.
Receiver operating characteristic curve analyses for
SOFA score alone, for the GIF score based on the number
of GI symptoms and their combination are presented in
Table 6. ROC curves including GIF score were not sig-
nificantly different from the ROC curves of the SOFA
score alone.
Discussion
The current prospective worldwide multicentre study
including critically ill patients with an expected duration
of mechanical ventilation of more than 6 h demonstrated
that a large proportion of these patients had GI symptoms
during the first week of admission. Some specific symp-
toms, including absent BS, GI bleeding and bowel
distension, as well as the total number of GI symptoms,
were associated with 28 day mortality. Furthermore, an
increasing number of GI symptoms predicted outcome
independently. However, the study failed to develop an
additional dysfunction score that significantly improved
mortality prediction of the SOFA score.
The total incidence, as well as the occurrence of the
individual GI symptoms, was comparable to earlier
observations [1–4], despite the fact that the definitions for
these symptoms differ somewhat between studies. The
proportion of patients with two or more simultaneous GI
symptoms was lower in the present study (20 %) than in a
Table 1 Patient characteristics on admission and day 1 among survivors and nonsurvivors
Characteristics All (n = 377) Survivors (n = 260) Nonsurvivors (n = 117) P value
Admission
Age, years, median (range) 62 (18–98) 61 (18–98) 64 (22–91) 0.082
Body mass index 26 (23–29) 26 (23–29) 25(22–29) 0.086
Medical profile, n (%) 142 (37.7) 84 (32.3) 58 (49.6) 0.001
Abdominal surgery, n (%) 118 (31.3) 90 (34.6) 28 (23.9) 0.042
Day 1
APACHE II score, points 18 (13–24) 17 (12–22) 21 (17–30) \0.001
Sepsis, n (%) 137 (36.3) 82 (31.5) 55 (47.0) 0.005
SOFA score (points) 8 (5–10) 7 (5–10) 10 (7–14) \0.001
Vasopressors, n (%) 263 (69.8) 172 (66.2) 91 (77.8) 0.029
pO2/FiO2 (mmHg) 188 (108–322) 193 (115–347) 177 (97–292) 0.151
Creatinine (lmol/L) 99 (72–164) 91 (69–139) 126 (80–188) \0.001
Glasgow coma scale (points) 13 (6–15) 14 (7–15) 10 (4–15) \0.001
Fluid balance (L/24 h) ?1.4 (0.4–2.9) ?1.1 (0.2–2.7) ?2.0 (1.0–3.5) 0.001
Urine output (L/24 h) 1.6 (0.9–2.6) 1.8 (1.0–2.7) 1.2 (0.4–2.3) \0.001
Mean IAP (mmHg) 9.8 (7.0–12.7) 10.0 (7.3–12.8) 9.0 (5.9–12.6) 0.066
Minimal APP (mmHg) 62 (52–71) 62 (53–72) 60 (46–70) 0.033
Number of GI symptoms 0 (0–1) 0 (0–1) 1 (0–1) 0.013
Three or more GI symptoms, n (%) 18 (4.8) 7 (2.7) 11 (9.4) 0.008
Data are median (interquartile ranges) if not stated otherwise
APACHE II score acute physiology and chronic health evaluation II
(11), SOFA score sequential organ failure assessment (8), pO2/FiO2
partial oxygen pressure in blood/content of oxygen in inspired air,
IAP intra-abdominal pressure, APP abdominal perfusion pressure,
GI gastrointestinal
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Table 2 Daily and global incidence of gastrointestinal (GI) symptoms, intra-abdominal hypertension and gastrointestinal failure among survivors and
non-survivors
Day 1 Day 2 Day 4 Day 7 Cumulative
Total number of patients 377 352 264 200 377
Survivors 260 244 194 147 260
Nonsurvivors 117 106 70 53 117
Median (IQR) number of GI symptoms Cumulative maximum#
Total 1 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 1 (0–2)
Survivors 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 1 (0–1)
Nonsurvivors 1 (0–1) 1 (0–1) 1 (0–1) 1 (0–1) 1 (0–2)
P value* \0.001 \0.001 \0.001 \0.001 \0.001
Absent bowel sounds
Total (%) 125 (33.2) 82 (23.3) 42 (15.9) 29 (14.9) 142 (37.7)
Survivors (%) 76 (29.2) 45 (18.4) 25 (12.9) 15 (10.3) 88 (33.8)
Nonsurvivors (%) 49 (41.9) 37 (34.9) 17 (24.3) 14 (28.6) 54 (46.2)
P value* 0.018 \0.001 0.033 0.009 0.022
Diarrhoea
Total (%) 26 (6.9) 40 (11.2) 46 (17.4) 39 (19.5) 81 (21.5)
Survivors (%) 16 (6.2) 20 (8.2) 31 (16.0) 26 (17.7) 53 (20.4)
Nonsurvivors (%) 10 (8.5) 20 (18.9) 15 (21.4) 13 (24.5) 28 (23.9)
P value* 0.388 0.006 0.270 0.314 0.498
Bowel distension
Total (%) 54 (14.3) 53 (15.1) 32 (12.9) 19 (9.5) 78 (20.7)
Survivors (%) 33 (12.7) 34 (13.9) 21 (11.5) 10 (6.8) 48 (18.5)
Nonsurvivors (%) 21 (17.9) 19 (17.9) 11 (16.7) 9 (17.0) 30 (25.6)
P value* 0.202 0.325 0.275 0.049 0.129
Vomiting/regurgitation
Total (%) 18 (4.8) 11 (3.1) 5 (1.9) 7 (3.5) 31 (15.5)
Survivors (%) 11 (4.2) 7 (2.9) 3 (1.5) 5 (3.4) 22 (8.5)
Nonsurvivors (%) 7 (6.0) 4 (3.8) 2 (2.9) 2 (3.8) 9 (7.7)
P value* 0.445 0.738 0.611 1.000 1.000
High gastric residual volume
Total (%) 13 (3.4) 8 (2.3) 8 (3.0) 8 (4.0) 28 (7.4)
Survivors (%) 8 (3.1) 5 (2.4) 5 (2.6) 5 (3.4) 15 (5.8)
Nonsurvivors (%) 5 (4.3) 3 (2.8) 3 (4.3) 3 (5.7) 13 (11.1)
P value* 0.556 0.706 0.712 0.697 0.086
Gastrointestinal bleeding
Total (%) 16 (4.2) 13 (3.7) 5 (1.9) 4 (2.0) 24 (6.4)
Survivors (%) 7 (2.7) 4 (1.6) 2 (1.0) 2 (1.4) 11 (4.2)
Nonsurvivors (%) 9 (7.7) 9 (8.5) 3 (4.3) 2 (3.8) 13 (11.1)
P value* 0.049 0.003 0.116 0.270 0.020
At least 1 GI symptom
Total 168 (44.6) 146 (41.7) 109 (41.3) 81 (40.5) 227 (60.2)
Survivors 105 (40.4) 88 (33.8) 71 (27.3) 51 (19.6) 148 (56.9)
Nonsurvivors 63 (53.8) 58 (49.6) 38 (32.5) 30 (25.6) 79 (67.5)
P value* 0.019 0.001 0.011 0.009 0.054
2 or more GI symptoms
Total 62 (16.4) 46 (13.1) 21 (8.0) 20 (10.0) 76 (20.2)
Survivors 39 (15.0) 24 (9.2) 13 (5.0) 10 (3.8) 44 (16.9)
Nonsurvivors 23 (19.7) 22 (18.8) 8 (6.8) 10 (8.5) 32 (27.4)
P value* 0.293 0.009 0.203 0.017 0.026
3 or more GI symptoms = GI failure
Total (%) 18 (4.8) 11 (3.1) 6 (2.3) 3 (1.5) 24 (6.4)
Survivors (%) 7 (2.7) 2 (0.8) 1 (0.5) 1 (0.7) 9 (3.5)
Nonsurvivors (%) 11 (9.4) 9 (8.5) 5 (7.1) 2 (3.8) 15 (12.8)
P value* 0.008 0.001 0.006 0.172 0.001
4 or more GI symptoms
Total 4 (1.1) 11 (3.1) 0 1 (0.5) 16 (4.2)
Survivors 2 (0.8) 2 (0.8) 0 1 (0.4) 5 (1.9)
Nonsurvivors 2 (1.7) 9 (7.7) 0 0 11 (9.4)
P value* 0.591 0.001 0.002
Intra-abdominal hypertension
Total (%) 109 (28.9) 96 (27.4) 68 (25.8) 40 (20.0) 161 (42.7)
Survivors (%) 77 (29.6) 71 (29.1) 55 (28.4) 32 (21.8) 111(42.7)
Nonsurvivors (%) 32 (27.4) 25 (23.6) 13 (18.6) 8 (15.1) 50 (42.7)
P value* 0.713 0.421 0.105 0.305 1.000
* P values refer to comparisons between survivors and nonsurvivors
# Maximal daily sum of GI symptoms
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previous single-centre study (36 %) [4]. An increasing
number of GI symptoms was related to increased mor-
tality in both studies [4]. In the present study, absent BS,
GI bleeding and bowel distension were the symptoms and
signs associated with mortality, similar to earlier findings
[4]. Another previously reported finding that a combina-
tion of IAH and FI predicted outcome [9] could not be
confirmed in this study, as unfortunately there was a high
rate of missing data for the reasons to withhold or reduce
EN. Thus, although a final GIF score is still not formu-
lated, occurrence of GIF is, independently of its exact
formulation, associated with adverse outcome in all
studies.
A major limitation of assessment of GI symptoms is
that some of the symptoms are subjective and poorly
defined, the most questioned being absent BS. There is a
consensus not using absent BS as a reason to withhold
enteral nutrition [13]. Absence of BS still should be
considered pathological, however. Consistent association
of absent BS (despite the obvious limitations of this
symptom) with mortality is an important finding of our
study. An explanation might be that absence of BS
reflects severity of inflammation and hypoperfusion, but
also deeper sedation and immobilisation often required
for artificial organ support (cardiac assist devices, ECMO,
CVVH etc.). The exact doses of sedation and analgesia
were not recorded in the present study. There is one
previous observation that absent or abnormal BS are
associated with higher mortality in univariate analysis [4].
A high incidence of IAH was observed in the study
population (42.7 % compared to 27–30 % in some pre-
vious studies [9, 14]). The possibility to measure IAP was
an inclusion criterion, the reason being that previous
studies have shown a relation between IAH and mortality
Table 3 Multivariate regression analyses with GI symptoms, failure of enteral nutrition, and intra-abdominal hypertension predicting
28 day survival
Day 1 P value OR Lower CI 95 % Upper CI 95 %
Absent bowel sounds 0.007 2.457 1.285 4.700
Vomiting/regurgitation 0.877 0.903 0.25 3.258
Maximum GRV [ 500 ml 0.888 0.910 0.244 3.397
Diarrhoea 0.387 1.700 0.511 5.659
Bowel distension 0.916 0.954 0.398 2.289
GI bleeding 0.042 4.404 1.058 18.333
EN \ 80 % of caloric needs 0.032 0.325 0.116 0.906
IAH 0.316 0.708 0.361 1.390
DAY 2
Absent bowel sounds 0.425 1.368 0.633 2.957
Vomiting/regurgitation 0.887 1.120 0.234 5.352
Maximum GRV [ 500 ml 0.673 1.392 0.300 6.469
Diarrhoea 0.408 1.640 0.508 5.289
Bowel distension 0.759 1.162 0.445 3.030
GI bleeding 0.008 19.093 2.153 169.336
EN \ 80 % of caloric needs 0.040 0.355 0.132 0.952
IAH 0.062 0.461 0.204 1.041
DAY 4
Absent bowel sounds 0.192 1.793 0.746 4.310
Vomiting/regurgitation 0.366 3.147 0.263 37.699
Maximum GRV [ 500 ml 0.398 1.995 0.402 9.901
Diarrhoea 0.361 1.642 0.567 4.758
Bowel distension 0.829 1.122 0.396 3.173
GI bleeding 0.150 5.595 0.538 58.177
EN \ 80 % of caloric needs 0.440 1.437 0.573 3.605
IAH 0.127 0.512 0.217 1.210
DAY 7
Absent bowel sounds 0.162 2.157 0.735 6.332
Vomiting/regurgitation 0.230 0.162 0.008 3.158
Maximum GRV [ 500 ml 0.636 1.490 0.285 7.790
Diarrhea 0.793 1.181 0.342 4.083
Bowel distension 0.036 7.070 1.140 43.859
GI bleeding 0.249 3.822 0.392 37.281
EN \ 80 % of caloric needs 0.951 0.970 0.364 2.582
IAH 0.153 0.428 0.134 1.372
The variables entered into the multivariate analysis were exclusively those listed above
Significant findings are marked in bold
GRV gastric residual volume, GI gastrointestinal, EN enteral nutrition, IAH intra-abdominal hypertension
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[9, 15]. Furthermore, the IAP value is numerical and
reproducible, and as such could be considered as a
parameter for a SOFA GI sub-score [12]. The proportion
of patients in whom transvesical pressure measurement is
not possible (mainly post-cystectomy patients) is extre-
mely small in a general ICU population. In the present
study, IAH was not associated with increased mortality,
confirming the findings of a recently published study [16].
There are several possible reasons for failure to
improve the predictive value of the SOFA score by
including a GI dysfunction score. First, there might be a
type-II statistical error, since we did not meet our
enrolment goal. The goal was based on expected enrol-
ment rates for a fixed study period, but on retrospect the
actual enrolment control could have improved our study
design. With inclusion of patients on MV for at least 6 h
we aimed to minimize the inclusion of ‘‘recovery room
patients’’ and concentrate on ‘‘real’’ ICU patients.
Exclusion of spontaneously breathing patients was plan-
ned because of different pathophysiological patterns of
IAP during MV. Unfortunately, selection bias must have
occurred, as in some centres patient enrolment was
unexpectedly low and at the same time severity of illness
and associated mortality were higher than expected. In a
previous study on GI dysfunction enrolling all MV
patients staying in ICU for 24 h and showing that GIF
score increased the predictive power of the SOFA score
[9] mean APACHE II score (14 vs. 19) and therefore also
predicted mortality (19 vs. 32 %) [11] were lower than in
the present study. Compared to earlier studies in unse-
lected ICU patients, we also observed a rather limited
performance of SOFA score predicting mortality [17, 18].
In particular, the cardiovascular subscore of SOFA, usu-
ally the best-performing subscore [9, 19], had a low
power in our study. The relative high proportion of
patients receiving vasoactive drugs, resulting in high
cardiovascular subscores, additionally confirms that the
sickest patients were included. The inclusion of more
severely ill patients and associated lower diversity of
patients might explain that both SOFA and GI score
poorly predicted mortality. Moreover, the fact that addi-
tion of GI dysfunction did not improve the predictive
power of the SOFA score may actually be an important
finding of the study. It leads us to the hypothesis that in
this general ICU population of severely ill patients not
‘‘primary GI failure’’ due to abdominal pathology is the
main problem, but rather ‘‘secondary GI failure’’ due to
systemic inflammation and/or hypoperfusion.
The majority of the patients did not reach their caloric
needs via the enteral route, but in many cases the exact
reasons were not documented. This may reflect daily
practice in study units. These missing data made it
impossible to identify the impact of FI on outcome in this
study. Former studies have defined FI as\80 % of caloric
needs achieved after 48–72 h in the ICU [20] or as
withholding EN for any GI reason [9]. In both cases, this
highly depends on the local feeding strategy and nutri-
tional goals, which remain controversial for critically ill
patients during the initial phase of critical illness [21–23].
Our observation of EN \ 80 % being associated with
better survival is likely biased by not initiating enteral
nutrition in patients with an expected oral intake within a
couple of days [24].
Several biomarkers reflecting intestinal function have
been suggested recently (I-FABP, citrulline, D-lactate)
[25, 26]. Future studies should establish their place in clin-
ical practice and establish their correlations with clinical GI
signs and symptoms, as well as with prognosis [27].
Fig. 2 Kaplan–Meier survival plot for patients with GIF versus
without GIF. Grey line shows less than three GI symptoms
concomitantly during the first week in ICU. Black line shows at
least three GI symptoms concomitantly during the first week in
ICU. P \ 0.001 between the groups (Log-rank test)
Table 4 Multivariate regression analysis with admission day
variables predicting 28-day mortality
P value Odds ratio 95 % CI
Age 0.542 1.005 0.990–1.019
Body mass index 0.207 0.971 0.929–1.016
Medical profile 0.083 1.598 0.940–2.716
Sepsis 0.223 1.400 0.815–2.406
Fluid balance day 1 0.859 1.000 1.000–1.000
Three or more GI symptoms
day 1
0.035 3.189 1.082–9.396
Renal SOFA sub-score <0.001 1.423 1.169–1.733
Neurological SOFA sub-score <0.001 1.444 1.231–1.694
Haematologic SOFA sub-score 0.073 1.277 0.977–1.668
Respiratory SOFA sub-score 0.311 1.113 0.905–1.368
Hepatic SOFA sub-score 0.804 0.962 0.710–1.305
Cardiovascular SOFA sub-score 0.859 0.982 0.808–1.195
Nagelkerke R-square 0.253
The table presents the final model of multivariate analysis after
removal of clearly correlated variables
Significant findings are marked in bold
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Despite being the largest prospective multicentre
international study to assess the GI dysfunction in MV
patients, the current study has several limitations. First,
most of the GI dysfunction definitions are subjective, an
issue currently limiting the research in this area. Second,
missing data was a considerable problem in our study,
mainly because the FI could not be identified in many
cases. Third, even though the inclusion of a wide variety
of ICUs have made the results more generalizable, it
might as well be considered as a limitation due to asso-
ciated variations in treatment practice. Fourth, the aimed
number of patients was not reached in our study. A
greater number of patients is needed to create a reliable
score in future studies. Fifth, the exclusion of patients
with an expected short ventilation period makes our
results apply to a population of more severely ill ICU
population.
Conclusions
The current prospective worldwide multicentre study
shows that a severely ill subgroup of mechanically ven-
tilated ICU patients frequently has GI symptoms and IAH.
Absent bowel sounds, GI bleeding, and an increasing
number of coincident GI symptoms were associated with
28-day mortality. Based on the data of this study it was
however not possible to develop a valid GI dysfunction
score that improved the accuracy of the SOFA score.
Table 5 Regression analyses with daily SOFA sub-scores and the number of GI symptoms as an additional sub-score predicting 28-day
mortality
SOFA sub-scores ? number of GI symptoms, and survival
Day 1 P value OR Lower CI 95 % Upper CI 95 %
SOFA cardiovascular 0.757 1.030 0.854 1.242
SOFA respiratory 0.133 1.158 0.956 1.403
SOFA haematologic 0.075 1.261 0.977 1.628
SOFA hepatic 0.774 0.958 0.718 1.280
SOFA renal \0.001 1.441 1.193 1.740
SOFA neurological \0.001 1.469 1.262 1.710
Number of GI symptoms 0.089 1.264 0.965 1.656
Day 2
SOFA cardiovascular 0.799 1.025 0.847 1.240
SOFA respiratory 0.261 1.119 0.919 1.363
SOFA haematologic 0.286 1.151 0.889 1.491
SOFA hepatic 0.738 0.940 0.653 1.353
SOFA renal 0.007 1.309 1.077 1.592
SOFA neurological \0.001 1.331 1.146 1.546
Number of GI symptoms 0.002 1.606 1.184 2.179
Day 4
SOFA cardiovascular 0.961 1.006 0.801 1.263
SOFA respiratory 0.447 1.105 0.854 1.432
SOFA haematologic 0.364 1.156 0.846 1.579
SOFA hepatic 0.771 1.061 0.713 1.577
SOFA renal 0.009 1.381 1.083 1.762
SOFA neurological 0.001 1.348 1.122 1.620
Number of GI symptoms 0.054 1.505 0.993 2.282
Day 7
SOFA cardiovascular 0.133 1.227 0.940 1.603
SOFA respiratory 0.656 1.075 0.782 1.478
SOFA haematologic 0.045 1.502 1.008 2.237
SOFA hepatic 0.371 0.806 0.503 1.292
SOFA renal 0.588 1.082 0.814 1.438
SOFA neurological 0.045 1.238 1.005 1.525
Number of GI symptoms 0.010 1.882 1.164 3.042
Cumulative maximum
SOFA cardiovascular 0.454 1.080 0.883 1.320
SOFA respiratory 0.390 1.101 0.884 1.371
SOFA haematologic 0.561 1.072 0.847 1.357
SOFA hepatic 0.888 1.020 0.777 1.338
SOFA renal \0.001 1.475 1.246 1.747
SOFA neurological \0.001 1.452 1.254 1.681
Number of GI symptoms 0.082 1.267 0.971 1.655
GI gastrointestinal, SOFA sequential organ failure assessment
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This may either be due to data set limitations, definition
problems, or may indicate that GI dysfunction is often
secondary to and not the primary cause of other organ
failure. A larger study is needed to unravel this possible
interaction.
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